Background: Denosumab, a RANK-ligand inhibitor, is an effective treatment for osteoporosis in postmenopausal women and men. Unlike the bisphosphonates, it is not excreted by the kidney. Little is known, however, about its efficacy and safety in patients with severe chronic kidney disease (CKD). Methods: A retrospective study was performed in CKD 4-5D patients from a tertiary referral hospital who were treated with denosumab between 1st January 2011 and 31st March 2014. Data collected included information about the following: CKD stage, fracture history, bone mineral density, serum calcium levels pre and post denosumab treatment, episodes of hypocalcemia, relevant medications and adverse events. Results: Eight patients with CKD-5 and 6 patients with CKD-4 were identified (all female, mean age 77.1 ± 9.9). The mean pre-denosumab calcium value was 2.42 ± 0.12 mmol/l, PTH 20.2 ± 14.7 pmol/l and 25-OH vitamin D 69.1 ± 30.1 nmol/l. After denosumab treatment, 6/8 patients with CKD-5/5D, and 2/5 patients with CKD-4 developed severe hypocalcemia. Two patients developed direct adverse complications of hypocalcemia (seizure, laryngospasm, prolonged QTc). Among the patients who developed hypocalcemia, the median time to serum calcium nadir was 21 days and the median time to correction of hypocalcemia was 71 days. Treatment of hypocalcemia required large doses of oral calcium and calcitriol, and increases in dialysate calcium concentration. Conclusions: A high rate of severe hypocalcemia was observed in patients with advanced CKD treated with denosumab. If denosumab is used in patients with severe CKD, close monitoring and aggressive replacement of calcium and calcitriol is required to avoid the development of hypocalcemia.

Keywords:
Hypocalcemia, Chronic kidney disease, Chronic kidney disease mineral and bone disorder
1.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1-S130.
2.
Klawansky S, Komaroff E, Cavanaugh PF Jr, et al: Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 2003;14:570-576.
3.
Leinau L, Perazella MA: Hip fractures in end-stage renal disease patients: incidence, risk factors, and prevention. Semin Dial 2006;19:75-79.
4.
Bliuc D, Nguyen ND, Milch VE, et al: Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:513-521.
5.
Gordon PL, Frassetto LA: Management of osteoporosis in CKD Stages 3 to 5. Am J Kidney Dis 2010;55:941-956.
6.
Miller PD: Bone disease in CKD: a focus on osteoporosis diagnosis and management. Am J Kidney Dis 2014;64:290-304.
7.
Toussaint ND, Elder GJ, Kerr PG: Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 2009;4:221-233.
8.
Cummings SR, San Martin J, McClung MR, et al: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-765.
9.
Block GA, Bone HG, Fang L, et al: A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012;27:1471-1479.
10.
McCormick BB, Davis J, Burns KD: Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 2012;60:626-628.
11.
Ungprasert P, Cheungpasitporn W, Srivali N, et al: Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emerg Med 2013;31:756.e1-e2.
12.
Working Group of the Australian and New Zealand Bone and Mineral Society; Endocrine Society of Australia; Osteoporosis Australia: Vitamin D and adult bone health in Australia and New Zealand: a position statement. Med J Aust 2005;182:281-285.
13.
Diab DL, Watts NB: Denosumab in osteoporosis. Expert Opin Drug Saf 2014;13:247-253.
14.
Jamal SA, West SL, Miller PD: Bone and kidney disease: diagnostic and therapeutic implications. Curr Rheumatol Rep 2012;14:217-223.
15.
Gal-Moscovici A, Sprague SM: Osteoporosis and chronic kidney disease. Semin Dial 2007;20:423-430.
16.
Jamal SA, West SL, Miller PD: Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int 2012;23:1191-1198.
17.
Ho LT, Sprague SM: Women and CKD-mineral and bone disorder. Adv Chronic Kidney Dis 2013;20:423-426.
18.
Jamal SA, Ljunggren O, Stehman-Breen C, et al: Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 2011;26:1829-1835.
19.
Chen CL, Chen NC, Hsu CY, et al: An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab 2014;99:2426-2432.
20.
Medwatch The FDA Safety Information and Adverse Event Reporting Program. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm343116.htm.
21.
Bashour T, Basha HS, Cheng TO: Hypocalcemic cardiomyopathy. Chest 1980;78:663-665.
22.
Cheng ML, Fong L: Effects of RANKL-targeted therapy in immunity and cancer. Front Oncol 2014;3:329.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.